Treatment for TTR amyloidosis + Treatment for TTR amyloidosis
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transthyretin (TTR) Amyloid Cardiomyopathy
Conditions
Transthyretin (TTR) Amyloid Cardiomyopathy
Trial Timeline
Oct 3, 2019 → Mar 27, 2025
NCT ID
NCT04108091About Treatment for TTR amyloidosis + Treatment for TTR amyloidosis
Treatment for TTR amyloidosis + Treatment for TTR amyloidosis is a pre-clinical stage product being developed by Pfizer for Transthyretin (TTR) Amyloid Cardiomyopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT04108091. Target conditions include Transthyretin (TTR) Amyloid Cardiomyopathy.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04108091 | Pre-clinical | Completed |
Competing Products
20 competing products in Transthyretin (TTR) Amyloid Cardiomyopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eplontersen Solution for Injection | AstraZeneca | Phase 1 | 33 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 77 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | AstraZeneca | Pre-clinical | 23 |
| Eplontersen | AstraZeneca | Phase 3 | 77 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 77 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 3 | 76 |
| NNC6019-0001 | Novo Nordisk | Phase 2 | 51 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 2 | 51 |
| Coramitug | Novo Nordisk | Phase 1 | 32 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| tafamidis meglumine | Pfizer | Approved | 84 |
| Fx-1006A | Pfizer | Phase 2 | 51 |
| Tafamidis | Pfizer | Phase 3 | 76 |
| Tafamidis 61 milligrams | Pfizer | Pre-clinical | 22 |
| Vyndaqel | Pfizer | Pre-clinical | 22 |
| tafamidis | Pfizer | Phase 3 | 76 |
| Tafamidis | Pfizer | Approved | 84 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| Vyndamax (tafamidis 61mg) | Pfizer | Pre-clinical | 22 |